Beech Tree Labs Inc. of Providence, R.I., has started a Phase 1/2a clinical trial  for its UISH001 therapeutic agent to treat urinary incontinence.
The placebo-controlled trial will involve 60 patients. Urinary incontinence affects about 200 million people worldwide, according to the National Association for Continence. In the United States, 25 million adults have transient or chronic incontinence, with upwards of 80 percent of those being women. One-third of men and women aged 30 to 70 have lost bladder control at some point in their adult lives. Managing urinary incontinence costs more than $20 billion in the United States alone. The condition becomes more common as people age.